Latest Insider Transactions at Aurinia Pharmaceuticals Inc. (AUPH)
This section provides a real-time view of insider transactions for Aurinia Pharmaceuticals Inc. (AUPH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aurinia Pharmaceuticals Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aurinia Pharmaceuticals Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 21
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
87,500
-33.1%
|
$2,100,000
$24.02 P/Share
|
|
Sep 21
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
87,500
+9.71%
|
$787,500
$9.91 P/Share
|
|
Sep 20
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
28,500
-7.19%
|
$598,500
$21.66 P/Share
|
|
Sep 20
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,500
+12.19%
|
$142,500
$5.3 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
44,000
-10.42%
|
$924,000
$21.76 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
134,000
+15.97%
|
$536,000
$4.6 P/Share
|
|
Sep 14
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
22,500
-17.5%
|
$472,500
$21.75 P/Share
|
|
Sep 14
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
90,000
-33.73%
|
$1,890,000
$21.19 P/Share
|
|
Sep 13
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
150,000
+34.3%
|
$450,000
$3.2 P/Share
|
|
Sep 13
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+11.02%
|
$125,000
$5.3 P/Share
|
|
Sep 10
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
150,000
-52.21%
|
$2,850,000
$19.84 P/Share
|
|
Sep 10
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
10,000
-3.68%
|
$190,000
$19.8 P/Share
|
|
Sep 10
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
25,000
-12.38%
|
$475,000
$19.8 P/Share
|
|
Sep 07
2021
|
Robert Bindert Huizinga EVP of Research |
SELL
Open market or private sale
|
Direct |
5,000
-3.48%
|
$90,000
$18.3 P/Share
|
|
Sep 07
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
7,500
-4.07%
|
$135,000
$18.1 P/Share
|
|
Aug 26
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
22,500
-10.88%
|
$382,500
$17.81 P/Share
|
|
Aug 25
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,000
-3.51%
|
$75,000
$15.85 P/Share
|
|
Aug 09
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.36%
|
$80,000
$16.01 P/Share
|
|
Aug 09
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
45,000
-24.03%
|
$720,000
$16.03 P/Share
|
|
Jul 28
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.31%
|
$65,000
$13.86 P/Share
|
|
Jun 22
2021
|
Michael Robert Martin Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,000
-2.25%
|
$65,000
$13.76 P/Share
|
|
May 12
2021
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
3,000
+22.6%
|
$33,000
$11.27 P/Share
|
|
May 11
2021
|
R. Hector Mac Kay Dunn |
BUY
Open market or private purchase
|
Direct |
1,500
+22.5%
|
$16,500
$11.16 P/Share
|
|
May 11
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
2,500
+40.32%
|
$25,000
$10.96 P/Share
|
|
May 11
2021
|
Michael Robert Martin Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+8.27%
|
$60,000
$3.02 P/Share
|
|
May 11
2021
|
Peter Greenleaf Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,125
+17.57%
|
$51,250
$10.63 P/Share
|
|
May 11
2021
|
Matthew Maxwell Donley EVP, Ops & Strategy |
BUY
Open market or private purchase
|
Direct |
9,900
+50.0%
|
$99,000
$10.07 P/Share
|
|
May 11
2021
|
Joseph M Miller Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$9,000
$9.74 P/Share
|
|
May 11
2021
|
Robert Bindert Huizinga EVP of Research |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+21.79%
|
$120,000
$3.02 P/Share
|
|
Mar 12
2021
|
Neil Solomons Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
40,000
-17.6%
|
$520,000
$13.49 P/Share
|
|
Mar 12
2021
|
Neil Solomons Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+14.96%
|
$120,000
$3.02 P/Share
|
|
Mar 05
2021
|
George M Milne Jr Director |
BUY
Open market or private purchase
|
Direct |
5,000
+10.0%
|
$65,000
$13.0 P/Share
|
|
Jan 29
2021
|
Michael R Hayden Director |
BUY
Exercise of conversion of derivative security
|
Direct |
95,000
+30.3%
|
$475,000
$5.97 P/Share
|
|
Jan 29
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Direct |
1,200
+50.0%
|
$19,200
$16.03 P/Share
|
|
Jan 29
2021
|
Jill Leversage Director |
BUY
Open market or private purchase
|
Indirect |
400
+50.0%
|
$6,400
$16.03 P/Share
|
|
Jan 28
2021
|
Stephen P. Robertson EVP, General Counsel |
BUY
Open market or private purchase
|
Direct |
900
+24.86%
|
$14,400
$16.14 P/Share
|